At the news
? NEUTRALIMPACT 3/10 6-K filed Jul 13, 2026 at 07:46 ET
Kamada announced positive results from an investigator-initiated study of CYTOGAM presented at the 2026 ISHLT annual meeting. The data suggest CYTOGAM use in CMV high-risk lung transplant recipients is associated with improved clinical outcomes and potential immune modulation benefits. While supportive of the product's profile, this is a press release highlighting existing clinical data, not a catalyst with quantifiable revenue impact, and represents routine scientific communication.
- Results from three posters on CYTOGAM (CMVIG) presented at the 2026 ISHLT annual meeting in Toronto
- Retrospective analysis showed CMV high-risk lung transplant recipients not receiving CMVIG had worse clinical outcomes vs those who received it
- Non-clinical in-vivo model suggested CMVIG blunted lung injury and improved mortality
- CYTOGAM is the sole FDA-approved immunoglobulin product for CMV prophylaxis in kidney, lung, liver, pancreas and heart transplantation
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access